利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.028 秒)

    LUNG CANCER MARKERS AND USES THEREOF
    1.
    发明申请
    LUNG CANCER MARKERS AND USES THEREOF 审中-公开
    肺癌标志物及其用途

    公开(公告)号：US20150037820A1

    公开(公告)日：2015-02-05

    申请号：US14331803

    申请日：2014-07-15

    申请人： Celera Corporation

    发明人： Charles BIRSE ,  Steve RUBEN ,  Marcia LEWIS ,  Mehdi MESRI

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57423 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57488 ,  G01N33/57492 ,  G01N2333/8114 ,  G01N2333/96486 ,  G01N2800/56

    摘要： Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.

    摘要翻译： 提供了使用肺癌标志物（LCM）评估（例如诊断），治疗和预防疾病，特别是癌症和特定肺癌的方法和组合物。 为这些和其他用途提供了单个LCM和包含多个LCM的面板。 还提供了用于确定或预测治疗的有效性或使用LCM选择治疗的方法和组合物。 还提供了使用LCM调节细胞功能的方法和组合物。 还提供了调节LCM的组合物（例如拮抗剂或激动剂），例如抗体，蛋白质，小分子化合物和核酸试剂（例如RNAi和反义剂），以及其药物组合物。 还提供了筛选调节LCM的试剂的方法以及通过这些筛选方法鉴定的试剂。

    LUNG CANCER MARKERS AND USES THEREOF
    2.
    发明申请
    LUNG CANCER MARKERS AND USES THEREOF 审中-公开

    公开(公告)号：US20200064347A1

    公开(公告)日：2020-02-27

    申请号：US16456363

    申请日：2019-06-28

    申请人： Celera Corporation

    发明人： Charles BIRSE ,  Steve RUBEN ,  Marcia LEWIS ,  Mehdi MESRI

    IPC分类号： G01N33/574 ,  C12Q1/6886

    摘要： Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.